Sherbrooke Park Advisers LLC Krystal Biotech, Inc. Transaction History
Sherbrooke Park Advisers LLC
- $436 Billion
- Q3 2024
A detailed history of Sherbrooke Park Advisers LLC transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Sherbrooke Park Advisers LLC holds 2,379 shares of KRYS stock, worth $462,858. This represents 0.1% of its overall portfolio holdings.
Number of Shares
2,379
Previous 1,335
78.2%
Holding current value
$462,858
Previous $245 Million
76.64%
% of portfolio
0.1%
Previous 0.04%
Shares
3 transactions
Others Institutions Holding KRYS
# of Institutions
311Shares Held
24.4MCall Options Held
483KPut Options Held
364K-
Black Rock Inc. New York, NY3.95MShares$768 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.85MShares$554 Million0.01% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.62MShares$510 Million7.18% of portfolio
-
State Street Corp Boston, MA1.45MShares$283 Million0.01% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA988KShares$192 Million9.67% of portfolio
About Krystal Biotech, Inc.
- Ticker KRYS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,664,300
- Market Cap $4.99B
- Description
- Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...